Rheumatology-Rhumatologie

📢 NEW REVIEW

Although psoriatic arthritis and rheumatoid arthritis are both common types of inflammatory arthritis characterised by synovial inflammation, there are distinct molecular and cellular landscapes between these conditions.

In this Review, Ryan Malcolm Hum and colleagues explore how research of the synovium has advanced the understanding of psoriatic arthritis, the potential of identified cell types and cytokines as biomarkers and novel therapeutic targets, how limited sample sizes in high-dimensional studies are hindering clinical translation, and the future directions for synovial research in psoriatic arthritis.
Maria Christofi, Lysette Marshall, NIHR Manchester Biomedical Research Centre (BRC)

Read the full Review here ➡️ https://lnkd.in/eFY6uAbF

Alt text: Previously identified cell types and cytokines implicated in psoriatic arthritis pathogenesis in the synovial fluid and synovial tissue

Sjögren’s Disease: A Name Change with Real Impact

A powerful reminder for all of us in the Sjögren’s community and especially here at the NECESSITY project: language matters.

Through international consensus, published in Nature Reviews Rheumatology, officially retired the term “Sjögren’s syndrome” in favor of “Sjögren’s disease”and eliminates the distinction between “primary” and “secondary” forms. From now on, Sjögren’s is Sjögren’s whether or not it occurs with another autoimmune condition.
This shift is far from symbolic, it’s a meaningful change that reflects the seriousness of this condition and the lived experience of millions.

✅ Disease, not syndrome: Recognizes Sjögren’s as a complex, systemic autoimmune disease—not just a loose cluster of symptoms.

✅ Goodbye “primary” and “secondary”: These outdated terms are replaced by “associated” when applicable, offering more accurate and less stigmatizing language.

✅ Why it matters: Terminology shapes how a disease is perceived, diagnosed, and treated. This update supports better care, stronger research, and deeper validation for patients.

As the Sjögren’s Foundation underscores in the linked article, it’s time for all of us, be it clinicians, researchers, journals, media, and advocates to embrace this change and reflect it in our work and communication carefully.

This is a meaningful step forward for scientific clarity, clinical progress, and, above all, for patients. 💙

https://lnkd.in/ex8jcE5C

#SjögrensDisease #AutoimmuneAwareness #PatientAdvocacy #MedicalTerminology #NatureReviewsRheumatology #SjögrensCommunity

Si vous rencontrez quelqu’un qui a les yeux secs, la bouche sèche, des douleurs, une fatigue chronique, c’est peut être parce que chacun de ces signes est fréquent. Mais c’est peut être dû à une maladie de Sjogren…..
Si voulez
- savoir ce qu’est cette maladie
- pourquoi on ne dit plus « Syndrome de sjogren » mais bien « Maladie de Sjogren »
- pourquoi on ne dit plus « Syndrome de Sjogren secondaire »
N’hésitez pas à télécharger cet article grâce au lien suivant:

https://rdcu.be/eqlz1


⸻

If you meet someone with dry eyes, a dry mouth, pain, or chronic fatigue, it might just be because each of these symptoms is common. But it could also be due to Sjögren’s disease…

If you want to:
• understand what this disease is,
• know why we no longer say “Sjögren’s syndrome” but rather “Sjögren’s disease”,
• learn why the term “secondary Sjögren’s syndrome” is no longer used,

feel free to download this article using the following link:

https://rdcu.be/eqlz1

The COVID-19 pandemic changed healthcare practices and social media played a significant role in those changes. While social media and online practice communities allow collaboration and engagement,

There is an ongoing search for novel biomarkers to enhance diagnosing and monitoring patients with rheumatic diseases (RDs). We conducted a systematic review and meta-analysis to investigate the potential role of the soluble cluster of differentiation 40 (sCD40) and sCD40 ligand (sCD40L), involved...

Figure 2. Overview of the pathogenesis and treatment of OA. In osteoarthritis (OA), alarmins are endogenous molecules released in response to various forms of damage. These molecules bind to pattern recognition receptors (PRRs) on different cells, triggering either an inflammatory or regenerative...

Systemic sclerosis (SSc) remains a challenging and enigmatic systemic autoimmune disease, owing to its complex pathogenesis, clinical and molecular heterogeneity, and the lack of effective disease-modifying treatments. Despite a century of research in SSc, the interconnections among microvascular dysfunction, autoimmune phenomena and tissue fibrosis in SSc remain unclear. The absence of validated biomarkers and reliable animal models complicates diagnosis and treatment, contributing to high morbidity and mortality. Advances in the past 5 years, such as single-cell RNA sequencing, next-generation sequencing, spatial biology, transcriptomics, genomics, proteomics, metabolomics, microbiome profiling and artificial intelligence, offer new avenues for identifying the early pathogenetic events that, once treated, could change the clinical history of SSc. Collaborative global efforts to integrate these approaches are crucial to developing a comprehensive, mechanistic understanding and enabling personalized therapies. Challenges include disease classification, clinical heterogeneity and the establishment of robust biomarkers for disease activity and progression. Innovative clinical trial designs and patient-centred approaches are essential for developing effective treatments. Emerging therapies, including cell-based and fibroblast-targeting treatments, show promise. Global cooperation, standardized protocols and interdisciplinary research are vital for advancing SSc research and improving patient outcomes. The integration of advanced research techniques holds the potential for important breakthroughs in the diagnosis, treatment and care of individuals with SSc. The diagnosis, treatment and management of systemic sclerosis (SSc) remains challenging, owing to the complexity of this disease. In this Perspective, an international group of experts discuss the future of SSc research and how the advent of innovative technologies will advance research into and understanding of SSc.

Big thanks to Korng Ea for delivering a fantastic talk at the last ITN INTEC #ISSEC webinar before the summer break!
We also wish to express our gratitude to all the other speakers who contributed throughout the first semester 2025 series Makarand Risbud Christoph Winkler @Vicky Macrae @José-Luis Millan Anabela Bensimon Brito
Finally, thank you to all attendees for your active participation, which has been making this series a great success. See you in a few months with a new program built by Flóra Szeri, PhD

www.crd.york.ac.uk/prosperoi dentifier is CRD42024592972.

Our immune system is armed with an array of defenses designed to detect and eliminate harmful threats. One of its most powerful defense mechanisms is the complement system—a group of proteins that patrols our body, ever vigilant for signs of infection or injury. Now, over 100 years after the complement system was first described, researchers at Mass General Brigham have discovered that a protein known as granzyme K (GZMK) drives tissue damage and inflammation by activating the complement system against our own tissues.